This model has also demonstrated a possible role for CXCL11 in anti-CTCL treatment (Hensbergen et al., 2005), revealed the role of TSLP in promoting a Th2-dominant tumor environment (Takahashi et al., 2016), and identified galectin-9 as a potential new therapeutic target for CTCL (Vieyra-Garcia et al., 2016). The gene discussed is LGALS9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.